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Background: Left ventricular hypertrophy and myocardial remodelling occur with aortic valve disease and may lead to heart failure. Although increased oxidative stress and inflammatory factors have been implicated in heart failure, their role in the progression of valve disease remains unclear. 
Objectives: We investigated the role of oxidative stress and inflammatory factors in valve disease whether this relates to cell death. 
Methods: Blood samples were taken from 24 patients with valve disease before surgery and the results were compared with those from blood samples from 30 control healthy subjects. Myocardial biopsies from patients with valve disease were also collected before cannulation of the right atrial appendage. NF-B activities in atrial and mononuclear cells nuclear extracts were determined by electrophoretic mobility shift assay.
Results: Nuclear factor kappaB activities were significantly greater in mononuclear cells from AVD patients compared with healthy controls and the antigens were detectable in atrial tissues valve disease patients. Plasma C-reactive protein, B-natriuretic peptides, plasma tumor necrosis factor alpha and soluble tumor necrosis factor receptor 1 and 3-nitrotyrosine levels were significantly higher in valve disease patients. Inducible nitric oxide and 3-nitrotyrosine antigens and cells expressing CD45 antigens were detected within atrial tissues obtained from valve disease patients suggesting oxidative stress originated from in situ leukocytes. 
Conclusions: The findings suggests that oxidative stress originating from in situ leukocytes within the atrial myocardium may be the potential trigger for excessive transcriptional activities and apoptotic cell death within the atrial myocardium of valve disease patients. This represents a potential therapeutic target.

INTRODUCTION
Aortic valve disease (AVD) manifests as stenosis and/or valve incompetence that may trigger cardiac hypertrophy to compensate for the altered workload [1]. In the adult population, the principal cause of aortic stenosis is the deposition of calcium within the aortic valve leaflets and persistent leaflet stress with each cardiac contraction causes shear stresses that progressively produce small deposits of calcium within the collagen network. Aortic regurgitation on the other hand, occurs when aortic valve leaflets fail to adjust fully during diastole to provide an effective opening between the aorta and the left ventricle and thus allows previously ejected blood to flow retrograde into the left ventricular chamber. The main causes of aortic valve incompetence were rheumatic disease, medio-necrosis, congenital malformation, bacterial endocarditis, and trauma. 

Epidemiological studies have demonstrated that chronic cardiac hypertrophy is a major independent risk factor for the morbidity and mortality in the general population [2] and that aortic valve disease is associated with hypertrophic remodeling of the heart due to the left ventricular (LV) diastolic and systolic dysfunction and may lead to the development of congestive heart failure that is associated with oxidative stress [3] and the release of inflammatory factors such as c-reactive proteins [4-5]. Evidence in the literature has shown that endogenous cardiac hormones atrial natriuretic peptides, B-type natriuretic peptide (BNP) and its aminoterminal portion N-BNP may have a role in the progression of congestive heart failure [6], and that the levels of these peptides correlate with New York Heart Association symptom class and LV function. They are also known to be independent prognostic markers of cardiovascular outcomes [6] and sudden death in patients with cardiac failure [6].

In AVD however, the molecular stresses and adaptive responses triggered by volume overload and myocardial stretching are not fully understood. What is known is that the release of natriuretic peptides reflects severity of aortic valve stenosis disease and that the levels also represent the worsening of symptoms [7]. Whether oxidative stress or inflammatory factors play roles in the induction of hypertrophy and cardiac remodeling is unclear in patients with aortic valve disease. In this study, we determined levels of redox-sensitive transcription factor NF-B, oxidative stress, natriuretic peptides and inflammatory factors in blood and the myocardium of patients with aortic valve disease and explored whether pathological changes relate to apoptotic cell death.

METHODS
The study was approved by our local Medical Ethics Committee (East Midlands Ethics Committee, UK) and was conducted in accordance with the Helsinki declaration, and that all the participating patients that were undergoing aortic valve operations gave informed consent. 
Patients’ selection criteria and recruitment: Patients were identified from the hospital surgical waiting list and were recruited during their attendance of outpatients’ preoperative clinic irrespective of the underlying cause of disease. Consecutive patients were included if they were 18 years or older and had a planned elective aortic valve replacement surgery. Study information was provided to participants at least 24 hours before informed consent was given.  
A total of 24 consecutive patients were included in the study, 7 stenotic, 5 regurgitant and 12 with mixed aortic valve disease. Exclusion criteria were diabetes mellitus, patients on steroids and non-steroid anti-inflammatory agents, chronic obstructive pulmonary disease, coronary artery disease and malignancy. Atrial appendages were collected from patients during right atrial cannulation and prior to the initiation of cardiopulmonary bypass and were immediately frozen in liquid nitrogen. Blood samples were collected from patients preoperatively 24 hours prior to the operations and also from 30 healthy controls. All samples were coded and blood samples were processed in the laboratory for plasma and leukocyte buffy coat that were stored at -800C until analysis. Codes were broken to reveal the identity of the donor after the completion of all the analyses. 

Tissue and leukocytes homogenization: Total protein extracts were prepared by homogenizing atrial biopsies collected from patients before initiation of cardiopulmonary bypass. Atrial appendages were immediately frozen in liquid nitrogen and subsequently ground to a powder while still frozen using a pestle and mortar. Powdered atrial tissues were lysed in lysing buffer containing 50 mM Tris buffer, pH 7.4, 1 mM EGTA, 0.1% beta-mercaptoethanol, 150 mM NaCL, 1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF), 0.8 µM aprotinin, 20 µM leupeptin, 15 µM E65, 50 µM bestatin, 10 µM pepstatin, and 0.1% Triton X-100. Tissue lysates were further homogenizied using an Ultra-Turrax T25 homogenizer with a dispersing tool (IKA Laboratories, Staufen, Germany) at 20,000 rpm for 1 minute on ice. The tissue homogenates were then centrifuged at 1000 g for 5 minutes at 40C. The supernatants were transferred into pre-cooled tubes, snap frozen in liquid nitrogen and stored at -800C until analysis.

Oxidative stress determination: Plasma, mononuclear cells and myocardial oxidative stress were determined by the measurement of protein 3-nitrotyrosine content and lipid hydroperoxides (ROOH) concentration. Protein 3-nitrotyrosine was determined by a sensitive ELISA previously described [8] and lipid ROOH were measured by the FOX-II assay (ferrous oxidation in xylenol orange) as previously described [9].

Detection of inducible NOS protein by western blot: Tissue and mononuclear cell lysates were separated for iNOS by electrophoresis on a 7.5% SDS/PAGE. The presence of iNOS was detected by immunoblotting using a monoclonal anti-iNOS and an anti-mouse HRP conjugate. All the antibodies used in this part of the study were obtained from CN Biosciences, Nottingham, UK. The immunoblot signal was visualized through enhanced chemiluminescence and scanned with an Epson Expression 1600 Pro. The relative intensities of bands were determined using NIH Image 1.62 package.

Assays for TNF- and TNF-receptor I in tissue homogenates and plasma: TNF- and s-TNF-receptor I (s-TNF-RI) were determined by standard ELISAs purchased from BD Pharmingen, CA. 

Plasma 8-iso-Prostaglandin-F2α extraction and assay: The 8-epimer of Prostaglandin F2α (8-iso-PGF2α) is produced in vivo by both non-cyclooxygenase and cyclooxygenase dependent mechanisms from arachidonic acid [10]. It has been postulated to participate as an inflammatory and pathophysiological mediator that is also able to modify the fluidity and integrity of membranes that it circulates in plasma and is excreted in urine [11]. 8-iso-PGF2α was extracted from plasma by alkaline hydrolysis followed by acid neutralization and levels determined by a competitive immunoassay kit from Assay designs, Inc., Ann Arbor, MI.   

CRP measurement: CRP was determined as an inflammatory marker and this was performed using a commercially available ELISA kits from IBL GmbH, Hamburg, Germany. 

Plasma B-type natriuretic peptide (BNP) assay: Congestive heart failure is associated with the release of endogenous cardiac hormones B-type natriuretic peptides and these were determined in plasma as a marker of progression of congestive heart failure using a highly sensitive peptide enzyme immunoassay available from Peninsula Laboratories, San Carlos, CA. The within-assay coefficients of variation of 4.8% and intra-assay coefficients of variation of 6% were observed for BNP measurements.

Nuclear extracts and Electrophoretic mobility shift assay (EMSA): Nuclear extracts and EMSA were as previously described [12] using frozen powdered atrial tissue and leukocyte buffy coat. Double stranded oligonucleotides containing the consensus binding sequences of NF-B (5’-AGT TGA GGG GAC TTT CCC AGG C-3 and 3’-TCA ACT CCC CTG AAA GGG TCC G-5’) were purchased from Promega, Southampton, UK. Biotin end-labelled DNA duplex sequences above and containing putative binding sites for NF-B were incubated with the nuclear extracts from atrial tissue, mononuclear cells and a control sample from HeLa cells nuclear extracts. After the reaction the DNA-protein complexes were subjected to a 6% native polyacrylamide gel electrophoresis and transferred to nylon membranes (Biodyne B membrane also supplied by Pierce). A chemiluminescent detection method utilising a luminol/enhancer solution and a stable peroxide solution (Pierce, UK), was used as described by the manufacturer and membranes were exposed to X-ray films for 2-5 minutes before developing. The bands were scanned with an Epson Expression 1600 Pro and relative intensities were analysed by using NIH Image 1.62 package.

Preparation of tissue sections for in situ detection of antigens: Immunohistochemistry was also performed on myocardial tissues using the frozen right atrial biopsies obtained from all the study patients. Fresh biopsies were immediately fixed in 4% paraformaldehyde for 2 hours, snap frozen in liquid nitrogen and stored in -800C. Frozen sections were mounted on glass slides, rehydrated in humidified chambers. Antigen unmasking was performed by treatment with proteinase K (20 μg/ml) and microwaving in 0.1 M trisodium citrate/0.1% Triton X-100.

Detection of atrial tissue levels of NF-B (p65/RelA), CD45 and iNOS
After a rinsing in PBS, tissue sections were then peroxidase blocked for 5 minutes and washed twice in PBS. The slides were incubated at room temperature for 30 minutes with 3% bovine serum albumin diluted in PBS. After washing twice in PBS the slides were incubated with specific primary antibody solutions (50 mM Tris HCl/1% BSA) for 30 minutes at room temperature. The primary antibodies used for iNOS2 (Santa Cruz; cat: sc-7271), and NF-B subunit p65/Rel A (Santa Cruz) and CD45 (DAKO) were mouse monoclonal. The slides were washed 3 times for 30 minutes in PBS and incubated for 60 minutes at room temperature with peroxidase-labelled polymer conjugated to goat anti-mouse immunoglobins. Detection was by DAKO EnVision+ system peroxidase (DAB) kit as described by the manufacturer (DAKO UK) and counterstained with haematoxylin and eosin.

Co-localisation of 3-nitrotyrosines and apoptotic cell death within atrial tissues:
After a rinsing in PBS, tissue sections were then peroxidase blocked for 5 minutes and washed twice in PBS. The slides were incubated at room temperature for 30 minutes with 3% bovine serum albumin diluted in PBS. After washing twice in PBS the slides were incubated with specific primary antibody solutions (50 mM Tris HCl/1% BSA) for 30 minutes at room temperature. The primary antibodies used were monoclonal anti-mouse for 3-nitrotyrosine (Upstate Biotechnology). The slides were washed 3 times for 30 minutes in PBS and incubated for 60 minutes at room temperature with goat anti-mouse IgG (H+L) highly cross-adsorbed secondary antibody with Alexa Fluor Plus 555. To determine whether 3-notrotyrosines (markers of oxidative stress) co-localise with apoptotic cell death in cells, some tissue sections from above were used prior to addition of the secondary antibody. A standard test for the terminal deoxynucleotidal transferase-mediated dUTP nick-end labelling (TUNEL) was performed and positive cells were detected using the in situ cell death detection kit (Roche, Penberg, Germany). Briefly, tissue sections were incubated with a reaction mixture containing TdT which catalyses polymerisation of labelled nucleotides to free 3’-OH DNA ends in a template-independent manner and the fluorescein (dUTP) incorporated into nucleotide polymers. The slides were counterstained after washing 3 times for 30 minutes in PBS and incubated for 60 minutes at room temperature with goat anti-mouse IgG (H+L) highly cross-adsorbed secondary antibody with Alexa Fluor Plus 555. Presence of 3-nitrotyrosines and TUNEL positive cells was detected by fluorescence microscopy.

Statistical analyses: The results are reported as mean ± SEM. Differences between means were determined by a one-way ANOVA followed by a Newman Keul’s test for post hoc comparisons. Linear regression analysis and Spearman rank correlation were used to compare the different parameters determined. P-values <0.05 were considered significant.

RESULTS
The clinical characteristics of the study patients are summarized in Table 1. This shows that in the mean LV ejection fractions, aortic valve velocity, area and posterior wall thickness were not significantly different between patients with stenotic, regurgitant and mixed aortic valve disease. Peak aortic gradient was also not significantly different between patients with stenotic versus mixed valve disease, whereas, in contrast, regurgitant patients had significantly greater degree of valve incompetence than the former (P<0.05). Table 2, shows that there was no significant difference between aortic valve patients and healthy controls in terms of age, male: female ratio and history of hypertension.

Oxidative stress: Figure 1A-1D show that protein 3-nitrotyrosine and lipid hydroperoxides levels, markers of oxidative stress, were greater in plasma of patients with aortic valve disease compared with healthy controls. The results also show that in patients with AVD significantly higher levels in oxidative stress markers exist in mononuclear cell extracts compared with the myocardial tissue extracts. 

iNOS expression: Figure 2A, show demonstrate that the iNOS content was also significantly greater in mononuclear cells from AVD patients compared with healthy controls. Figures 2B-2C also shows that the iNOS activity levels in the mononuclear cells for AVD patients were markedly higher than in the myocardium. The observations suggest that nitric oxide (NO) metabolism is predominantly elevated in mononuclear cells compared with atrial myocardium tissue in patients with AVD. 

Inflammatory factors: Figures 3A-3B demonstrates that TNF- and TNF-R1 from mononuclear cells extracts and plasma were significantly greater in patients with AVD compared with healthy controls. Figure 3C-3D indicates that CRP and 8-isoprostane levels were significantly higher in plasma from AVD patients compared with healthy controls. 

Release of endogenous cardiac hormones B-type natriuretic peptides: Figure 4 shows that plasma BNP levels were significantly greater in AVD patients compared with healthy controls.

Transcriptional activities: Figure 5 shows a sample of extracts from both atrial tissue and mononuclear cells from AVD patients with positive nuclear translocation and DNA-binding activities of NF-B. There are comparatively higher levels of NF-B transcriptional activities in mononuclear cell nuclear extracts from AVD patients compared with healthy controls. 

Immunohistochemical detection of p65/RelA (NF-B subunits), CD45 and iNOS in the right atrial appendage sections: Figures 6A show positive staining within the atrial myocardial tissue for p65/RelA. Figures 6B-6C show both iNOS and CD45 positive cells were amply detectable within the atrial tissue microvascular, indicating that the source is mostly from mononuclear leukocytes by origin.

Co-localisation of 3-nitrotyrosines and apoptotic cell death
Figure 7A-C shows that cells loaded with 3-nitrotyrosines were present within the right atrial tissue. In addition, Figure 8A-B shows that 3-nitrotyrosines were co-localised in the vicinity of TUNEL positive cells which is as a marker of impending apoptotic cell death.

DISCUSSION
This study has shown that in patients with aortic valve disease, blood and circulating mononuclear cells have an elevated oxidative stress, NO metabolism and inflammatory factors compared with healthy controls. This response in patients with aortic valve disease may mediate in part the activation of redox-sensitive transcription factors NF-B in both mononuclear cells and the myocardium. These findings strengthen the view that increased oxidative stress and inflammatory factors may be key elements in the pathogenesis of aortic valve disease and progression to hypertrophy and heart failure. The results provide novel evidence on the systems and mechanisms that may be responsible for the propagation of hypertrophic response in patients with aortic valve disease. 

In general, adult cardiac myocytes are believed not to possess replicative properties and that any increase in myocardial mass is entirely dependent on increases in myocytes size. The findings from this study suggest that impaired aortic valve function acts as the stimuli for cardiac hypertrophy and involves the switch for induction of expression of various genes in each myocardial cell occurring in response to increasing pressure. One such mechanism may involve the increased release of inflammatory factors, growth factors and oxidant free radicals mediated via activation of gene transcription factors of the cells of the myocardium and circulating mononuclear cells as evidenced from this study. Other experimental studies have shown that oxidant free radicals and inflammatory factors may themselves be the mediators of the activation of redox-sensitive transcriptional factor activities NF-B and AP-1 [13] to promote fibroblast proliferation and upregulation of the expression of genes involved in cardiac remodeling such as transforming growth factor beta (TGF) [14]. In the case of oxidative stress, evidence from this study suggests that this originates predominantly from tissue infiltrating mononuclear leukocytes that induce activation of transcription factors NF-B via. The oxidative stress mediated apoptotic cell death may be partly supported by increased iNOS expression and resultant Peroxynitrite within the infiltrating tissue mononuclear leukocytes. Indeed, previously, we have shown that Peroxynitrite-induced oxidative stress is an essential feature of monocytes cytokine response via activation of NF-B [12]. 

In terms of the importance of inflammatory factors in the progression of hypertrophy and cardiac remodeling, our study has shown that patients with aortic valve disease have significantly higher plasma levels of CRP compared with healthy controls, an indication of a possible underlying systemic proinflammatory process. 

It is also of interest to note that levels of TNF-α in mononuclear cell extracts were significantly greater than those from healthy control subjects. The levels of TNF-α in mononuclear cells were similar to those in the myocardial tissue extracts from patients with aortic valve disease. Sustained over-expression of TNF-α cytokine within the myocardium is known to provoke an overt cardiac decompensation through increased myocytes loss, decreased myocytes contractility, and increased degradation and /or fibrosis of the extracellular matrix [15]. High levels of myocardial tissue TNF-α level are produced in response to volume and pressure overload that may lead to development of left ventricular hypertrophy and cardiomyopathy [16], a process that may be mediated by the activation of transcription factors [17]. Results from this study have also shown that arachidonic acid metabolites 8-iso-Prostanes are significantly elevated in patients with aortic valve disease in much the same way as CRP, an indication of a possible counter regulatory proinflammatory role, although more investigations are required to reveal the mechanism. It should be noted however, that the role of the above factors in the mechanisms leading to the activation of redox-sensitive transcription factors and cardiac hypertrophy still require a great deal of research and that other elements such as oxidized LDL, heparin sulphate, mechanical stretch may also play a significant role [18].

The results from our study also suggest that instrumental to the induction of proinflammatory mechanisms is activation of oxidative stress within the myocardium which is predominantly mediated by activated mononuclear leukocytes that translocate into the tissue. Such proinflammatory processes include the regulation of levels of cell-associated TNF-receptors that are shed into the systemic circulation. This is demonstrated in our study by the greater plasma TNF-RI levels in aortic valve disease patients compared with healthy controls, an observation that may suggest a possible negative feedback mechanism for regulating increased TNF-α synthesis in both the myocardium and mononuclear cells. These findings are consistent with the literature where tumor necrosis factor soluble receptors are expressed in patients with varying degrees of congestive heart failure [19], suggesting that aortic valve disease follows a pathway of gradual decline to heart failure. Another possible regulatory mechanisms in opposition to the effect of TGF on cardiac remodeling, is the release of cardiac neuro-hormonal peptides BNP [6], indicating a perturbation of the cardiac neuro-hormonal system by valve disease that may signal the progression towards heart failure. Evidence suggests that BNP may play a major role in controlling hypertrophy and fibrosis [20]. 

In conclusion, our study has shown that there is an increased oxidative stress and inflammatory factors of patients with aortic valve disease that are strongly related to the activation of redox-sensitive transcription factors predominantly in mononuclear cells and less so in the myocardium. In aortic valve disease, these transcriptional factors may play an important role in the pathophysiology of cardiac hypertrophy and remodeling in response to increased pressure overload and left ventricular diastolic dysfunction. In contrast, the release of B-type natriuretic peptides acts to suppress the onset of cardiac hypertrophy and remodeling. The suppression of the activity of circulating mononuclear cells by blockade of NF-B and AP-1 activities seems like a possible therapeutic target however caution must be exercised to avoid affecting the immune system.
The findings from this study although limited by the small sample size and non-representation of all causes of aortic valve disease, however, the carefully selected patient group which excluded those with commodities such as diabetes, hypertension and smoking history known risk factors for heart disease minimised their influence and potential contribution to background interference. We acknowledge that the aetiology of aortic valve disease in the developed countries is predominantly due to aging-related degenerative disease including hypertension and atherosclerosis so the findings may be reflective of these causes. Despite the careful selection of patients to ensure that no participant had an underlying inflammatory disease, we cannot rule out that in some of the participants the findings may be related to un-reported underlying rheumatic and autoimmune disorders. In addition, the absence of results from myocardial tissue obtained from healthy controls we cannot be absolutely certain that  these observations are not normal background physiological processes and therefore the interpretation of the findings have to be considered with caution.
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Figure 1: Myocardial and mononuclear cells levels of 3-nitrotyrosine (A) and lipid ROOH (B), and plasma levels of 3-nitrotyrosine (C) and lipid ROOH (D) in patients with aortic valve disease (AVD) and in healthy controls. The bars represent the SEM; * P<0.05 versus the healthy control group; † P<0.05 versus mononuclear cells values within the AVD group.

Figure 2: Myocardial and mononuclear cells content of iNOS in AVD patients and in healthy controls. The bars represent the SEM; *P<0.05 versus the healthy control group; † P<0.05 versus mononuclear cell values within the AVD group.

Figure 3: Plasma levels of TNF-α (A), TNF-R1 (B), CRP (C) and 8-iso-Prostanes (D) and myocardial and mononuclear cells TNF-α (E) and TNF-R1 (F) in patients with AVD and in healthy controls. The bars represent the SEM; *P<0.05 versus the healthy control group; †P<0.05 versus mononuclear cell values within the AVD group.

Figure 4: Plasma levels of BNP in AVD patients and in healthy controls. The bars represent the SEM; * P<0.05 versus the healthy control group.

Figure 5: Figure 5A – shows detection of NF-B activities in atrial tissue nuclear extracts from patients with AVD. In addition, NF-B activities for mononuclear leukocytes nuclear extracts from AVD patients was compared those from healthy controls. 

Figure 6: Immunohistochemical detection of (A) p65/RelA; (B) iNOS; (C) CD65 antigens in atrial tissues. Figure A shows that p65/RelA antigens are detectable within the atrial tissue. In contrast Figures 5B and 5C indicate that expression of iNOS was within the atrial microvasculature by cells that were CD45 positive (leukocyte origin).





Table 1: Patients characteristics (mean SE)
	Stenotic AV	Regurgitant AV	Mixed AV disease
Number of subjects	7	5	12
Male: female 	4:3	2:3	8:4
LV ejection fraction %	66.008.00	70.005.00	60.006.00
Peak aortic velocity (m/s)	3.400.30	3.500.60	4.500.40
Posterior wall (diastole, cm)	0.800.08	0.720.10	0.900.07
Aortic valve area (cm2)	0.750.04	0.720.05	0.690.06
Peak aortic gradient (mmHg)	89.009.00	-	79.007.00
Regurgitation grade 	-	3.100.40 *	1.700.20

AV=aortic valve; * P<0.05 versus mixed disease

Table 2: Demographic data for all participants
	AVR patients	Healthy controls
Number of participants 	24	30




* P<0.05 versus healthy controls; AVR= aortic valve disease




